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brimonidine 0.2% ophthalmic solution. METHODS:
Randomized, controlled trials were conducted in 743
patients to evaluate the original formulation vs. the new
formulation. The new formulation reduced the concen-
tration of the active ingredient from 0.2% to 0.15% and
replaced the preservative, benzalkonium chloride (BAK),
with Purite. Patient outcomes assessed were satisfaction
and comfort level with the product. The economic 
evaluation model estimated the annual cost per patient
including pharmacy and medical ofﬁce visits (including
those that may occur due to adverse events.) RESULTS:
More patients were satisﬁed with the new formulation
(83%) than the original (75%) (p < 0.05). Eighty-ﬁve
percent of patients reported the new formulation was
comfortable vs. 79% for the original. Clinical efﬁcacy (as
measured by IOP reduction) was not different between
the groups. Approximately 90% of the new formulation
patients had no reported ocular allergy (OA) vs. 84% of
the patients using the original formulation (p < 0.05).
Incidence of OA was the primary cost driver in compar-
ing the two formulations, as patients who develop an
ocular allergy require additional resources associated
with OA. The economic model estimated the cost of an
OA patient was $200 more or 36% higher per year than
for an OA free patient, which results in higher overall
treatment costs associated with the original formulation.
CONCLUSIONS: Patients receiving the new reformu-
lated 0.15% brimonidine, rated their treatment satisfac-
tion and comfort level higher than patients on the original
formulation while experiencing the same level of efﬁcacy.
The estimated cost savings for ocular allergy-free patients
would have a positive impact on overall treatment costs.
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OBJECTIVES: To study the quality of life (QOL) of
patients with age related macular degeneration (AMD).
METHODS: A group of 81 subjects attending the low
vision and AMD clinic at the Princess Alexandra Eye
Pavilion in Edinburgh were given a battery of tests which
included the VFQ-25. We deﬁned AMD in the following
severity categories: mild, moderate and severe (dry or wet
AMD). In addition to the Quality of Life questionnaires,
patients were given a conjoint analysis task to complete.
The conjoint was to assess aspects of quality of life which
are rarely addressed in conventional questionnaires (i.e.,
patient values and relative importance of different daily
tasks). RESULTS: Background data on the patients
showed a mean age of 77yrs (SD = 6.8); mean binocular
distance logmar of 0.53 (SD = .43); mean binocular near
acuity of 0.7 (SD = 0.44); mean binocular contrast sensi-
tivity (Pelli Robson) of 1.17 (SD = 0.4). Sixty percent of
patients were classed as “severe” AMD, 28% of patients
as “moderate” AMD, and 12% of patients as “mild”
AMD. Results showed that the most signiﬁcant changes
in quality of life as reported through the questionnaires
occurred at the transition between moderate and severe
forms of the disease. The exception was emotionally rel-
evant questions and patient conﬁdence, which showed a
decline between all three AMD states. In addition con-
joint analysis showed that practical tasks associated with
independence had highest priority—that is the order 
of perceived importance from a 5-attribute conjoint task
was outdoor mobility, household chores, reading, recog-
nising faces, and glare. This rank order was preserved in
a shorter 3 attribute conjoint task given to patients with
extremely poor vision. CONCLUSIONS: The most sig-
niﬁcant change in QOL occurred between moderate and
severe forms of the disease. Patient concerns were mainly
over mobility and household tasks, suggesting a priority
for preserving an independent lifestyle.
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OBJECTIVES: Visual impairment has been identiﬁed as
one of the most signiﬁcant contributors to lost indepen-
dence, affecting 1.3 million people in the USA. An empha-
sis on improvement of functional limitations among
patients with visual impairment has led to the develop-
ment of vision-related quality of life (QOL) question-
naires in the recent past. The objective of this paper is 
to provide an updated review of published literature on
vision-related QOL instruments and an assessment of
their psychometric properties. METHODS: A review 
of published literature was carried out through the use 
of MEDLINE and QOLID in order to identify vision
related QOL instruments. The instruments were reviewed
in terms of reliability, validity and sensitivity/responsive-
ness, as well as their length and applicability to various
eye disorders. RESULTS: Twenty-four vision-related
QOL instruments were identiﬁed, of which thirteen were
designed for self-administration. Length of the question-
naires varied from 10 to 136 items, and the structure of
scales also varied greatly. Most of the instruments showed
high internal consistency of scales but only few demon-
strated test-retest reliability. Ten of the instruments
focused primarily on visual function, while fourteen also
measured the impact of vision problems on functional
ability. The NEI-VFQ (51 items) and NEI-VFQ-25 are the
only self-administered questionnaires that evaluate eye-
related functional ability and that have shown evidence
of validity, internal consistency and responsiveness across
a broad range of eye disorders including glaucoma,
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cataracts, diabetic retinopathy, age-related macular
degeneration and cytomegalovirus retinitis. CONCLU-
SIONS: For research that requires a self-administered
measure of vision-related QOL, the NEI-VFQ-25 appears
to be the optimum choice. It has demonstrated accept-
able psychometric properties across several QOL
domains with minimal respondent burden.
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OBJECTIVES: The objective of this study was to assess
and descriptively compare the quality of life (QOL)
effects of hyperhidrosis (HH), as measured by the Der-
matology Life Quality Index (DLQI), relative to other
dermatological conditions with published DLQI scores.
METHODS: Primary hyperhidrosis patients asking for
care at the Dermatology Clinic of the University of
Würzburg completed the DLQI as part of a research study
to assess the quality of life burden resulting from 
hyperhidrosis. Patients were categorized by main site of
involvement (i.e. axillary, palmar, other) to identify any
focal location-dependent differences. In addition, a liter-
ature search was performed to identify published reports
of DLQI scores for hyperhidrosis and other dermatolog-
ical conditions. Mean DLQI total scores observed in this
clinic cohort were compared with those for other derma-
tological conditions to determine the relative QOL effects
of hyperhidrosis. RESULTS: DLQI data were collected
from 345 hyperhidrosis patients in the dermatology
clinic. Forty-two published reports of mean DLQI total
scores for dermatological conditions, including three for
hyperhidrosis, were identiﬁed. Mean DLQI total scores
for hyperhidrosis ranged from 9.9–18 indicating signiﬁ-
cant quality of life impairment. By focal location of
hyperhidrosis, reported ranges for mean DLQI total
scores were: palmar (8.8–18), axillary (10–17), facial
(12.5), and mixed (9.2–15.5). Overall, hyperhidrosis was
associated with similar or greater impairment than other
dermatological conditions including psoriasis (4.5–13.9),
eczema (4.1–16.2), and acne (4.3–9.3). Similar mean
DLQI total scores and ranges were observed for both axil-
lary and palmar hyperhidrosis. CONCLUSIONS: This
review suggests that the QOL effects of hyperhidrosis as
assessed by the DLQI are comparable to, and in most
cases greater than, other dermatological conditions for
which DLQI data are available.
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OBJECTIVES: Quality of life enables patients to assess
the different consequences of the disease and/or treat-
ment. Skin disorders have a strong impact on the patient’s
physical and psychological well-being and the numerous
quality of life studies carried out among adults are here
to conﬁrm this. However, very few studies have been 
performed to assess the quality of life in children. This 
is mainly attributable to the fact that there is a lack of 
questionnaires to do this. METHOD: A speciﬁc scale
developed by Professor A. FINLAY (C-DLQI—Children-
Dermatology Life Quality Index) is completed by each
child before starting the course of treatment at Avène
Hydrotherapy Center, after three weeks of treatment,
after three months and after 6 months. RESULTS: Every
year, Avène Hydrotherapy Center welcomes a growing
number of children suffering from chronic dermatosis. It
thus seemed relevant to assess the quality of life of these
children (4–15 years old). The following initial analysis
has been obtained from the 30 ﬁrst questionnaires 
completed upon inclusion and after 3 months. The DLQI
score upon inclusion was 23.58 and 11.60 after 3
months. The results show an improvement in the patient’s
quality of life 3 months after the hydrotherapy course 
of treatment. This difference is statistically signiﬁcant 
(p = 0.010). After 3 weeks of treatment, the C-DLQI score
was 20.3 (p = 20.32). CONCLUSION: These results
clearly show that even some time after the end of the
hydrotherapy course of treatment, quality of life in chil-
dren suffering from chronic dermatosis continues to be
improved.
PES15
THE FRENCH VERSION OF THE CARDIFF ACNE
DISABILITY INDEX 
Myon E1, Finlay A2,Verriere F3, Nocera T3,Taïeb C1
1Pierre Fabre SA, Boulogne Billancourt, France; 2University of
Wales, Cardiff, United Kingdom; 3Laboratoires
Dermatologiques Avène, Lavaur, France
OBJECTIVE: The objective of our work was to translate
the Cardiff Acne Disability Index (CADI) into French,
with careful attention to the linguistic aspects and the 
cultural context of the French patients. METHOD: The
CADI is a scale devised by Prof. R.J. Motley and A. Finlay
of Cardiff to assess the disability caused by acne. This
questionnaire has been used in numerous studies to eval-
uate the consequences of the disease in daily life or the
effects of different treatments. Following international
methodological recommendations, the CADI scale was
translated in a standardized way consisting of forward
translation, quality control, backward translation, and a
